Twin drug setbacks pile pressure on Novartis pipeline, CEO
TimesLive | 08.09.2026 21:26
Novartis AG said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days that sent the Swiss drugmaker’s shares down about 9% in one of its worst trading days on record.
